Search Result

Results for "

glucagon and glucagon-like peptide 1 (GLP-1)

" in MedChemExpress (MCE) Product Catalog:

標的別:	GCGR (50) GLP Receptor (79) Akt (4) AMPK (1) Apoptosis (4) Arrestin (1) Autophagy (1) Dipeptidyl Peptidase (19) Drug Intermediate (1) Endogenous Metabolite (11) ERK (11) G Protein-coupled Receptor Kinase (GRK) (1) GPR119 (4) Insulin Receptor (8) Interleukin Related (1) Isotope-Labeled Compounds (8) mAChR (1) MEK (3) MMP (3) Neuropeptide Y Receptor (1) NF-κB (2) Phosphodiesterase (PDE) (1) PI3K (1) PKA (11) PROTACs (1) Reactive Oxygen Species (ROS) (4) Reference Standards (8) Sirtuin (1) TGF-beta/Smad (2) TRP Channel (2)
研究分野別:	Cancer (4) Cardiovascular Disease (7) Endocrinology (1) Inflammation/Immunology (18) Metabolic Disease (120) Neurological Disease (9)

標的別:

GCGR (50)

GLP Receptor (79)

Akt (4)

AMPK (1)

Apoptosis (4)

Arrestin (1)

Autophagy (1)

Dipeptidyl Peptidase (19)

Drug Intermediate (1)

Endogenous Metabolite (11)

ERK (11)

G Protein-coupled Receptor Kinase (GRK) (1)

GPR119 (4)

Insulin Receptor (8)

Interleukin Related (1)

Isotope-Labeled Compounds (8)

mAChR (1)

MEK (3)

MMP (3)

Neuropeptide Y Receptor (1)

NF-κB (2)

Phosphodiesterase (PDE) (1)

PI3K (1)

PKA (11)

PROTACs (1)

Reactive Oxygen Species (ROS) (4)

Reference Standards (8)

Sirtuin (1)

TGF-beta/Smad (2)

TRP Channel (2)

研究分野別:

Cancer (4)

Cardiovascular Disease (7)

Endocrinology (1)

Inflammation/Immunology (18)

Metabolic Disease (120)

Neurological Disease (9)

133

阻害剤およびアゴニスト

ペプチド

阻害性抗体

天然物

同位体標識化合物

Targets Recommended: GLP Receptor GCGR RXFP Receptor Formyl Peptide Receptor (FPR) Peptide-Drug Conjugates (PDCs) Natriuretic Peptide Receptor (NPR) Connective Peptide CGRP Receptor Amyloid-β

製品番号	製品名	Target	研究分野	構造式

HY-P0014

Liraglutide Maximum Cited Publications 38 Publications Verification	GCGR GLP Receptor	Metabolic Disease Cancer
Liraglutide is a **glucagon-like peptide-1** (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

HY-P0264

Exendin(9-39) amide 30+ Cited Publications Avexitide	GLP Receptor	Metabolic Disease
Exendin(9-39) amide (Avexitide) is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for binding to *GLP-1* receptors, thereby antagonizing the effects of excess *GLP-1* secretion. Exendin(9-39) amide can be used to study postoperative hypoglycemia (PBH) .

HY-112185

Orforglipron 1 Publications Verification LY3502970; GLP-1 receptor agonist 1	GCGR	Metabolic Disease Inflammation/Immunology
Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete .

HY-P3506

Retatrutide 3 Publications Verification LY3437943	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .

HY-125824

Danuglipron 4 Publications Verification PF-06882961	GCGR	Metabolic Disease
Danuglipron (PF-06882961) is an orally active **glucagon-like peptide-1 receptor (GLP-1R)** agonist. Danuglipron has the potential for type 2 diabetes research .

HY-13749

Sitagliptin 25+ Cited Publications MK-0431	Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK	Metabolic Disease
Sitagliptin (MK-0431) is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes .

HY-P0120

Dulaglutide 1 Publications Verification LY2189265	GCGR	Metabolic Disease
Dulaglutide (LY2189265) is a **glucagon-like peptide-1 (GLP-1)** receptor agonist. Dulaglutide can be uesd for the research of type 2 diabetes (T2D) .

HY-13749A

Sitagliptin phosphate 25+ Cited Publications MK-0431 phosphate	Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK	Metabolic Disease
Sitagliptin (MK-0431) phosphate is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin phosphate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate can be used for the study of 1-type and 2-type diabetes .

HY-P3366

Ecnoglutide XW003	GCGR	Metabolic Disease
Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-like peptide 1 *(GLP-1) receptor* agonist. Ecnoglutide can be used for research of T2DM and obesity .

HY-P0119

Lixisenatide 2 Publications Verification	GLP Receptor Akt MEK Apoptosis Reactive Oxygen Species (ROS) MMP	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lixisenatide is a **glucagon-like peptide-1** (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis .

HY-103546

BETP 1 Publications Verification	GCGR	Metabolic Disease
BETP is an agonist of glucagon-like peptide-1 (GLP-1) receptor, with EC₅₀s of 0.66 and 0.755 μM for human and rat GLP-1 receptor, respectively.

HY-13749B

Sitagliptin phosphate monohydrate 25+ Cited Publications MK-0431 phosphate monohydrate	Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK	Metabolic Disease
Sitagliptin (MK-0431) phosphate monohydrate is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin phosphate monohydrate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate monohydrate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate monohydrate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate monohydrate can be used for the study of 1-type and 2-type diabetes .

HY-112185A

Orforglipron hemicalcium hydrate 1 Publications Verification LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate	GCGR	Metabolic Disease Inflammation/Immunology
Orforglipron hemicalcium hydrate (LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate) is the calcium salt hydrate form of Orforglipron (HY-112185). Orforglipron is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorating the type 2 diabete .

HY-P3506A

Retatrutide TFA 3 Publications Verification LY3437943 TFA	GLP Receptor GCGR	Metabolic Disease
Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .

HY-P1141

GLP-1(9-36)amide	GCGR	Metabolic Disease
GLP-1(9-36)amide is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide acts as an antagonist to the human pancreatic GLP-1 receptor .

HY-156968

GLP-1 receptor agonist 14	GLP Receptor	Metabolic Disease
GLP-1 receptor agonist 14 (compound 474) is a potent agonist of glucagon-like peptide-1 (GLP-1). GLP-1 receptor agonist 14 plays an important role in diabetes or other metabolic disorders .

HY-129658A

TT-OAD2	GCGR	Metabolic Disease
TT-OAD2 is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC₅₀ of 5 nM. TT-OAD2 has the potential for diabetes treatment .

HY-P2231

Cotadutide 1 Publications Verification MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of **glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀** values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P2231A

Cotadutide acetate 1 Publications Verification MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of **glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀** values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P10957

Imapextide MBX 1416	GLP Receptor	Metabolic Disease
Imapextide is a glucagon-like peptide-1 (GLP-1) receptor antagonist that can be used in hypoglycemia research .

HY-112679

GLP-1 receptor agonist 2	GCGR	Inflammation/Immunology
GLP-1 receptor agonist 2 is a glucagon-like peptide-1 receptor *(GLP-1R)* agonist .

HY-N0630

Shanzhiside methyl ester 1 Publications Verification	GCGR	Neurological Disease
Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and has the ability to induce anti-allodynic tolerance .

HY-P1145

Glucagon-like peptide 1 (1-37), human 1 Publications Verification GLP-1 (1-37) human	GCGR	Metabolic Disease
Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.

HY-P2535

GLP-1 (7-36), amide, biotin labeled GLP-1 (7-36)-Lys(biotin)-amide	GLP Receptor	Metabolic Disease
Glucagon-Like Peptide 1 (GLP-1) (7-36)-Lys (Biotin), amide, human is an C-terminal-labelled biotinylated GLP-1 (7-36) amide.

HY-145458

PF-06954522 GLP-1 receptor agonist 9	GLP Receptor	Metabolic Disease
PF-06954522 is a glucagon-like peptide-1 receptor (GLP-1R) agonist. PF-06954522 is applicable to research related to type 2 diabetes .

HY-P11271

Ribupatide	Insulin Receptor GLP Receptor	Metabolic Disease
Ribupatide is a dual gastric inhibitory polypeptide (GIP) and **glucagon-like peptide 1 (GLP-1)** receptor agonist. Enicepatide can be studied in antidiabetic research .

HY-142162

LSN3318839	GCGR	Metabolic Disease
LSN3318839 is an orally active positive modulator of the **glucagon-like peptide-1 receptor (GLP-1R)**. LSN3318839 can increase the secretion of insulin and has the effect of lowering blood sugar .

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

HY-P10929

Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH	Drug Intermediate	Others
Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH is a drug intermediate in the synthesis of Tirzepatide. Tirzepatide is a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor (GLP-1R) agonist .

HY-P0014S1

Liraglutide-13C5,15N tetraTFA	Isotope-Labeled Compounds GLP Receptor GCGR	Others
Liraglutide- ¹³C₆, ¹⁵ tetraTFA is the ¹³C and ¹⁵N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-145412

GLP-1 receptor agonist 7	GLP Receptor	Metabolic Disease
GLP-1 receptor agonist 7 (Compound 130b) is a potent agonist of glucagon-like peptide-1 (GLP-1). GLP-1 receptor agonist 7 generates cAMP under the mediation of GLP-1R with an EC₅₀ of ≤ 0.2 nM. GLP-1 receptor agonist 7 can be used to study diseases related to the GLP-1 receptor (particularly type 2 diabetes) .

HY-P1145A

Glucagon-like peptide 1 (1-37), human TFA 1 Publications Verification HuGLP-1 TFA	GCGR	Metabolic Disease
Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor.

HY-P1144

Oxyntomodulin (bovine, porcine) glucagon-37 (bovine, porcine)	GCGR	Metabolic Disease
Oxyntomodulin (bovine, porcine), a 37-amino acid peptide hormone, is a glucagon-like peptide 1 (GLP-1) receptor agonist .

HY-P0165

Taspoglutide ITM077; R1583; BIM51077	GCGR	Metabolic Disease
Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC₅₀ value of 0.06 nM.

HY-P10018

Bamadutide SAR425899	GLP Receptor GCGR	Metabolic Disease
Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist. Bamadutide improves post-meal blood glucose control by significantly enhancing β-cell function and slowing down the rate of glucose absorption in the body. Bamadutide can be used for the research of metabolic diseases such as type 2 diabetes .

HY-P10269

Bofanglutide GZR18	GLP Receptor	Metabolic Disease
Bofanglutide (GZR18) is an analog of glucagon-like peptide-1 (GLP-1), which exhibits agonistic activity for GLP-1 receptor, with an EC₅₀ of 0.677 nM. GZR18 ameliorates type 2 diabetes .

HY-139276

Pal-Glu(OSu)-OH	GLP Receptor	Others
Pal-Glu(OSu)-OH is a side chain of Liraglutide. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used for type 2 diabetes mellitus research .

HY-P0264A

Exendin(9-39) amide acetate 30+ Cited Publications Avexitide acetate	GLP Receptor	Metabolic Disease
Exendin(9-39) amide (Avexitide) acetate is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for the GLP-1R, counteracting the effects of excessive GLP-1 secretion. Exendin(9-39) amide acetate can be utilized in Postbariatric hypoglycemia (PBH) research .

HY-P5815

GLP-1 (1-36) amide (human, rat) glucagon-like peptide 1 (1-36) amide (human, rat)	GLP Receptor GCGR	Metabolic Disease
GLP-1 (1-36) amide (human, rat) (Glucagon-like Peptide 1 (1-36) amide (human, rat) ) is a molecular variant of glucagon-like peptide 1 (GLP-1)-(7-36) amide. GLP-1 (1-36) amide (human, rat) can stimulate [14C]aminopyrine accumulation on enzymatically dispersed enriched rat parietal cells .

HY-144034

GLP-1R agonist 3	GLP Receptor	Metabolic Disease
GLP-1R agonist 3 is a potent agonist of *GLP-1R. GLP-1R* agonist 3 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 3 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 1) .

HY-P1348

GLP-1 moiety from Dulaglutide [Gly8,36,Glu22]-GLP-1 (7-37)	GCGR	Cardiovascular Disease Metabolic Disease
GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide. GLP-1 moiety from Dulaglutide is a glucagon-like peptide 1 receptor (GLP-1) agonist. Dulaglitude can be used in researches of diabetes and myocardial injury .

HY-P0014B

Liraglutide TFA Maximum Cited Publications 38 Publications Verification	GLP Receptor	Metabolic Disease
Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .

HY-P0119A

Lixisenatide acetate 2 Publications Verification	GLP Receptor Akt MEK Reactive Oxygen Species (ROS) Apoptosis MMP	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lixisenatide acetate is a **glucagon-like peptide-1** (GLP-1) receptor agonist. Lixisenatide acetate inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide acetate can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide acetate can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis .

HY-103433

K579	Dipeptidyl Peptidase	Metabolic Disease
K579 is a potent and orally active dipeptidyl peptidase IV inhibitor. K579 inhibits the blood glucose elevation. K579 increases the plasma insulin and active forms of glucagon-like peptide-1 (GLP-1). K579 has the potential for the research of diabetic .

HY-P5815A

GLP-1 (1-36) amide (human, rat) TFA glucagon-like peptide 1 (1-36) amide (human, rat) TFA	GLP Receptor GCGR	Metabolic Disease
GLP-1 (1-36) amide (human, rat) (Glucagon-like Peptide 1 (1-36) amide (human, rat) ) TFA is a molecular variant of glucagon-like peptide 1 (GLP-1)-(7-36) amide. GLP-1 (1-36) amide (human, rat) TFA can stimulate [14C]aminopyrine accumulation on enzymatically dispersed enriched rat parietal cells .

HY-108795

Albiglutide fragment GLP-1-Gly8; GLP-1 (7-36) analog	GLP Receptor	Metabolic Disease
Albiglutide fragment (GLP-1 (7-36) analog) is an active fragment of Albiglutide (7-36) and a glucagon-like peptide-1 (GLP-1) analog (a long-acting *GLP-1* receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-P2497

Exendin (5-39) 1 Publications Verification	GCGR	Neurological Disease
Exendin (5-39) is a potent glucagon-like peptide 1 (GLP-1) receptor antagonist. Exendin (5-39) improves memory impairment in β-amyloid protein-treated rats .

HY-P1141A

GLP-1(9-36)amide TFA	GCGR	Metabolic Disease
GLP-1(9-36)amide TFA is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide TFA acts as an antagonist to the human pancreatic GLP-1 receptor .

HY-E70397A

Dipeptidyl Peptidase IV, Porcine Kidney DPP-IV, Porcine Kidney	Dipeptidyl Peptidase	Metabolic Disease
Dipeptidyl Peptidase IV, Porcine Kidney (DPP-IV, Porcine Kidney) is a serine aminopeptidase with multiple physiological roles. Dipeptidyl Peptidase IV, Porcine Kidney hydrolyses gastric inhibitory peptide (GIP) and glucagon-like peptide 1 (GLP-1), the most important insulin-releasing hormones (incretins) of the enteroinsular axis .

製品番号	製品名	Target	研究分野

HY-P0014

Liraglutide Maximum Cited Publications 38 Publications Verification	GCGR GLP Receptor	Metabolic Disease Cancer
Liraglutide is a **glucagon-like peptide-1** (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

HY-P0264

Exendin(9-39) amide 30+ Cited Publications Avexitide	GLP Receptor	Metabolic Disease
Exendin(9-39) amide (Avexitide) is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for binding to *GLP-1* receptors, thereby antagonizing the effects of excess *GLP-1* secretion. Exendin(9-39) amide can be used to study postoperative hypoglycemia (PBH) .

HY-P3506

Retatrutide 3 Publications Verification LY3437943	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .

HY-P0120

Dulaglutide 1 Publications Verification LY2189265	GCGR	Metabolic Disease
Dulaglutide (LY2189265) is a **glucagon-like peptide-1 (GLP-1)** receptor agonist. Dulaglutide can be uesd for the research of type 2 diabetes (T2D) .

HY-P3366

Ecnoglutide XW003	GCGR	Metabolic Disease
Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-like peptide 1 *(GLP-1) receptor* agonist. Ecnoglutide can be used for research of T2DM and obesity .

HY-P0119

Lixisenatide 2 Publications Verification	GLP Receptor Akt MEK Apoptosis Reactive Oxygen Species (ROS) MMP	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lixisenatide is a **glucagon-like peptide-1** (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis .

HY-P3506A

Retatrutide TFA 3 Publications Verification LY3437943 TFA	GLP Receptor GCGR	Metabolic Disease
Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .

HY-P1141

GLP-1(9-36)amide	GCGR	Metabolic Disease
GLP-1(9-36)amide is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide acts as an antagonist to the human pancreatic GLP-1 receptor .

HY-P2231

Cotadutide 1 Publications Verification MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of **glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀** values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P2231A

Cotadutide acetate 1 Publications Verification MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of **glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀** values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P10957

Imapextide MBX 1416	GLP Receptor	Metabolic Disease
Imapextide is a glucagon-like peptide-1 (GLP-1) receptor antagonist that can be used in hypoglycemia research .

HY-P1145

Glucagon-like peptide 1 (1-37), human 1 Publications Verification GLP-1 (1-37) human	GCGR	Metabolic Disease
Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.

HY-P2535

GLP-1 (7-36), amide, biotin labeled GLP-1 (7-36)-Lys(biotin)-amide	GLP Receptor	Metabolic Disease
Glucagon-Like Peptide 1 (GLP-1) (7-36)-Lys (Biotin), amide, human is an C-terminal-labelled biotinylated GLP-1 (7-36) amide.

HY-P11271

Ribupatide	Insulin Receptor GLP Receptor	Metabolic Disease
Ribupatide is a dual gastric inhibitory polypeptide (GIP) and **glucagon-like peptide 1 (GLP-1)** receptor agonist. Enicepatide can be studied in antidiabetic research .

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

HY-P10929

Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH	Drug Intermediate	Others
Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH is a drug intermediate in the synthesis of Tirzepatide. Tirzepatide is a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor (GLP-1R) agonist .

HY-P0014S1

Liraglutide-13C5,15N tetraTFA	Isotope-Labeled Compounds GLP Receptor GCGR	Others
Liraglutide- ¹³C₆, ¹⁵ tetraTFA is the ¹³C and ¹⁵N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P1145A

Glucagon-like peptide 1 (1-37), human TFA 1 Publications Verification HuGLP-1 TFA	GCGR	Metabolic Disease
Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor.

HY-P1144

Oxyntomodulin (bovine, porcine) glucagon-37 (bovine, porcine)	GCGR	Metabolic Disease
Oxyntomodulin (bovine, porcine), a 37-amino acid peptide hormone, is a glucagon-like peptide 1 (GLP-1) receptor agonist .

HY-P0165

Taspoglutide ITM077; R1583; BIM51077	GCGR	Metabolic Disease
Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC₅₀ value of 0.06 nM.

HY-45894

tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu Semaglutide side chain	GLP Receptor	Metabolic Disease Inflammation/Immunology
tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu is an intermediate in the synthesis of the glucagon-like peptide 1 receptor (GLP-1R) agonist Semaglutide (HY-114118). tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu exhibits a strong binding affinity to albumin and can be used to modify SN38 prodrugs to improve tumor distribution .

HY-P10018

Bamadutide SAR425899	GLP Receptor GCGR	Metabolic Disease
Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist. Bamadutide improves post-meal blood glucose control by significantly enhancing β-cell function and slowing down the rate of glucose absorption in the body. Bamadutide can be used for the research of metabolic diseases such as type 2 diabetes .

HY-P10269

Bofanglutide GZR18	GLP Receptor	Metabolic Disease
Bofanglutide (GZR18) is an analog of glucagon-like peptide-1 (GLP-1), which exhibits agonistic activity for GLP-1 receptor, with an EC₅₀ of 0.677 nM. GZR18 ameliorates type 2 diabetes .

HY-P0264A

Exendin(9-39) amide acetate 30+ Cited Publications Avexitide acetate	GLP Receptor	Metabolic Disease
Exendin(9-39) amide (Avexitide) acetate is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for the GLP-1R, counteracting the effects of excessive GLP-1 secretion. Exendin(9-39) amide acetate can be utilized in Postbariatric hypoglycemia (PBH) research .

HY-P5815

GLP-1 (1-36) amide (human, rat) glucagon-like peptide 1 (1-36) amide (human, rat)	GLP Receptor GCGR	Metabolic Disease
GLP-1 (1-36) amide (human, rat) (Glucagon-like Peptide 1 (1-36) amide (human, rat) ) is a molecular variant of glucagon-like peptide 1 (GLP-1)-(7-36) amide. GLP-1 (1-36) amide (human, rat) can stimulate [14C]aminopyrine accumulation on enzymatically dispersed enriched rat parietal cells .

HY-P1348

GLP-1 moiety from Dulaglutide [Gly8,36,Glu22]-GLP-1 (7-37)	GCGR	Cardiovascular Disease Metabolic Disease
GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide. GLP-1 moiety from Dulaglutide is a glucagon-like peptide 1 receptor (GLP-1) agonist. Dulaglitude can be used in researches of diabetes and myocardial injury .

HY-P0014B

Liraglutide TFA Maximum Cited Publications 38 Publications Verification	GLP Receptor	Metabolic Disease
Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .

HY-P0119A

Lixisenatide acetate 2 Publications Verification	GLP Receptor Akt MEK Reactive Oxygen Species (ROS) Apoptosis MMP	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lixisenatide acetate is a **glucagon-like peptide-1** (GLP-1) receptor agonist. Lixisenatide acetate inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide acetate can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide acetate can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis .

HY-P3622

(Ser8)-GLP-1 (7-36) amide, human	GCGR	Metabolic Disease
(Ser8)-GLP-1 (7-36) amide, human is a glucagon-like peptide 1 amide derived from glucagonogen, a cleavage product of the GLP-1 (1-36) amide peptide. (Ser8)-GLP-1 (7-36) amide, human is an entero-insulinotropic hormone that causes glucose-dependent release of insulin from pancreatic β-cells and affects gastrointestinal motility and secretion .

HY-P5815A

GLP-1 (1-36) amide (human, rat) TFA glucagon-like peptide 1 (1-36) amide (human, rat) TFA	GLP Receptor GCGR	Metabolic Disease
GLP-1 (1-36) amide (human, rat) (Glucagon-like Peptide 1 (1-36) amide (human, rat) ) TFA is a molecular variant of glucagon-like peptide 1 (GLP-1)-(7-36) amide. GLP-1 (1-36) amide (human, rat) TFA can stimulate [14C]aminopyrine accumulation on enzymatically dispersed enriched rat parietal cells .

HY-108795

Albiglutide fragment GLP-1-Gly8; GLP-1 (7-36) analog	GLP Receptor	Metabolic Disease
Albiglutide fragment (GLP-1 (7-36) analog) is an active fragment of Albiglutide (7-36) and a glucagon-like peptide-1 (GLP-1) analog (a long-acting *GLP-1* receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-P2497

Exendin (5-39) 1 Publications Verification	GCGR	Neurological Disease
Exendin (5-39) is a potent glucagon-like peptide 1 (GLP-1) receptor antagonist. Exendin (5-39) improves memory impairment in β-amyloid protein-treated rats .

HY-P1141A

GLP-1(9-36)amide TFA	GCGR	Metabolic Disease
GLP-1(9-36)amide TFA is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide TFA acts as an antagonist to the human pancreatic GLP-1 receptor .

HY-P11235

Berobenatide PF-08653944; MET-097	GLP Receptor	Metabolic Disease
Berobenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist .

HY-P11271A

Ribupatide TFA	Insulin Receptor GLP Receptor	Metabolic Disease
Ribupatide TFA is a dual gastric inhibitory polypeptide (GIP) and **glucagon-like peptide 1 (GLP-1)** receptor agonist. Ribupatide TFA can be studied in antidiabetic research .

HY-P3506B

Retatrutide acetate LY3437943 acetate	GCGR GLP Receptor	Metabolic Disease
Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC₅₀ values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .

HY-P10591

Olatorepatide Olatorepatidum	Insulin Receptor GLP Receptor	Metabolic Disease
Olatorepatide (Olatorepatidum) is a dual gastric inhibitory polypeptide (GIP) receptor and glucagon like peptide 1 (GLP-1) receptor agonist, with antidiabetic effect .

HY-P3388

Utreglutide	GLP Receptor	Cardiovascular Disease Metabolic Disease
Utreglutide is an effective glucagon-like peptide 1 (GLP-1) receptor agonist. Utreglutide can lower blood pressure, blood lipids and body weight, and improve cardiovascular metabolism. Utreglutide can be used for research on type 2 diabetes or non-type 2 diabetes obesity .

HY-P0014AS

Liraglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor	Metabolic Disease
Liraglutide-d₈ tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P10302

GLP-1R/GIPR agonist-1	GLP Receptor Insulin Receptor	Metabolic Disease
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for *GLP-1* (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones *GLP-1* and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-P11237

Enicepatide CT-388	GCGR Insulin Receptor	Metabolic Disease
Enicepatide is a dual gastric inhibitory polypeptide (GIP) and **glucagon-like peptide 1 (GLP-1)** receptor agonist. Enicepatide can be studied in antidiabetic research .

HY-P11270

Relsipatide BGM0504; BG128	Insulin Receptor GLP Receptor	Metabolic Disease
Relsipatide (BG128) is a dual gastric inhibitory polypeptide (GIP) and **glucagon-like peptide 1 (GLP-1)** receptor agonist. Enicepatide can be studied in antidiabetic research .

HY-P10952

Astepatide	Insulin Receptor GLP Receptor	Metabolic Disease
Astepatide is a gastric inhibitory peptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in anti-diabetic research .

HY-P0014A

Liraglutide acetate	GLP Receptor	Metabolic Disease
Liraglutide acetate is the acetate form of Liraglutide (HY-P0014), a glucagon-like peptide-1 (GLP-1) receptor agonist studied in type 2 diabetes .

HY-P3539

Exendin-4 (3-39)	GCGR	Neurological Disease Endocrinology
Exendin-4 (3-39) is a *peptide. Exendin-4 (3-39) is a truncated form of Exendin-4 (HY-13443) that lacks the first two amino acids. Exendin-4 is a potent Glucagon-like* peptide-1 receptor (GLP-1r) agonist. Exendin-4 (3-39) and Exendin-4 can be used for the research of diabetic and hypothalamic-pituitary-adrenal (HPA) axis .

HY-P3491

Pegloxenatide Polyethylene glycol loxenatide; PEX 168	GCGR PI3K Akt Reactive Oxygen Species (ROS) Autophagy Interleukin Related Sirtuin AMPK Apoptosis	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Pegloxenatide (Polyethylene glycol loxenatide) is a long-acting glucagon-like peptide-1 receptor (GLP-1RA) agonist. Pegloxenatide has various activities such as lowering blood glucose, lowering blood lipids, improving body weight, anti-inflammation, promoting wound healing, protecting the liver, and protecting the heart. Pegloxenatide can be used in the research of type 2 diabetes and its multiple complications .

HY-P0014S2

Liraglutide-13C6,15N TFA	Isotope-Labeled Compounds	Others
Liraglutide- ¹³C₆, ¹⁵ TFA is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P10910

Vensemaglutide	GLP Receptor	Metabolic Disease
Vensemaglutide is the agonist for glucagon-like peptide 1 (GLP-1) receptor. Vensemaglutide can be used in research of diabetes or other metabolic disorders .

HY-P11043

GEP44	GLP Receptor Neuropeptide Y Receptor Arrestin	Metabolic Disease
GEP44 is a peptide biased triple agonist targeting **Glucagon-like peptide 1 receptor (GLP-1R), neuropeptide Y1 Receptor (Y1-R), and neuropeptide Y2 Receptor (Y2-R)*. GEP44 induces Y1-R antagonist-controlled, GLP-1R-dependent* stimulation of insulin secretion in both rat and human pancreatic islets by counteracting effects of Y1-R and GLP-1R agonism. GEP44 promotes insulin-independent Y1-R-mediated glucose uptake in muscle tissue and significantly reduces food intake and body weight in diet-induced obese rat models. GEP44 can be used for obesity and type 2 diabetes mellitus research .

製品番号	製品名	Target	研究分野	Image

HY-P990013

Gulgafafusp alfa Glutazumab; GMA-102; GMA-105	GCGR	Metabolic Disease
Gulgafafusp alfa is a human IgG2κ antibody targeting the glucagon-like peptide 1 receptor *GLP1R* .

製品番号	製品名	Category	Target	構造式

HY-W011121

2-Oleoylglycerol 1 Publications Verification 2-OG	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Lipid Source Classification	GPR119 NF-κB TGF-beta/Smad GLP Receptor
2-Oleoylglycerol (2-OG) is a lipid found in the diet. It is a GPR119 agonist, with an EC₅₀ value of 2.5 μM in activating hGPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol enhances the inflammatory response of macrophages and promotes fibrosis by activating the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. It also stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol is expected to be used in the research of non-alcoholic steatohepatitis (NASH) .

HY-N0630

Shanzhiside methyl ester 1 Publications Verification	Iridoids Terpenoids Labiatae Phaseolus lunatus L. Plants Source Classification	GCGR
Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and has the ability to induce anti-allodynic tolerance .

HY-N0630R

Shanzhiside methyl ester (Standard)	Structural Classification Iridoids Terpenoids Labiatae Phaseolus lunatus L. Plants Source Classification	Reference Standards GCGR
Shanzhiside methyl ester (Standard) is the analytical standard of Shanzhiside methyl ester. This product is intended for research and analytical applications. Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and has the ability to induce anti-allodynic tolerance .

HY-N18033

Glyceollin III	Structural Classification Monophenols Leguminosae Glycine max (L.) merr Phenols Plants Source Classification	Insulin Receptor GLP Receptor
Glyceollin III is a glyceollin found in soybeans. Glyceollin III enhances insulin-stimulated glucose uptake and increases glucagon-like peptide-1 (GLP-1) secretion. Glyceollin III can be used for the research of type 2 diabetes .

HY-113513

5-HEPE	Microorganisms Source Classification	Others
5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.

製品番号	製品名	構造式

HY-P0014S1

Liraglutide-13C5,15N tetraTFA
Liraglutide- ¹³C₆, ¹⁵ tetraTFA is the ¹³C and ¹⁵N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-13749AS

Sitagliptin-d4 phosphate

Sitagliptin-d₄ phosphate (MK-0431-d₄) is the deuterium labeled Sitagliptin phosphate (HY-13749A). Sitagliptin phosphate is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin phosphate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate can be used for the study of 1-type and 2-type diabetes.

HY-13749S1

Sitagliptin-d4 hydrochloride

Sitagliptin-d₄ hydrochloride is the deuterium labeled Sitagliptin hydrochloride (HY-13749E). Sitagliptin hydrochloride is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin hydrochloride blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin hydrochloride can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin hydrochloride shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin hydrochloride can be used for the study of 1-type and 2-type diabetes.

HY-P0014AS

Liraglutide-d8 tetraTFA
Liraglutide-d₈ tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P0014S2

Liraglutide-13C6,15N TFA
Liraglutide- ¹³C₆, ¹⁵ TFA is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-13749S3

Sitagliptin-d6

Sitagliptin-d₆ (MK-0431-d₆) is deuterium labeled Sitagliptin (HY-13749). Sitagliptin is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.

HY-13749S2

Sitagliptin-d4

Sitagliptin-d₄ (MK-0431-d₄) is deuterium labeled Sitagliptin (HY-13749). Sitagliptin is an orally active and highly selective DPP4 inhibitor with an IC₅₀ value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.

HY-P0119S

Lixisenatide (Leu-13C6,15N) TFA

Lixisenatide (Leu- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis .

HY-W701772

2-Oleoylglycerol-d5

2-Oleoylglycerol-d₅ (2-OG-d₅) is the deuterium labeled 2-Oleoylglycerol (HY-W011121). 2-Oleoylglycerol (2-OG) is a lipid found in the diet. It is a GPR119 agonist, with an EC₅₀ value of 2.5 μM in activating hGPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol enhances the inflammatory response of macrophages and promotes fibrosis by activating the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. It also stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol is expected to be used in the research of non-alcoholic steatohepatitis (NASH) .

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
タイトル			国或いは地域 *
お名前 *			組纖名 *
デパートメント *
メールアドレス *			製品名 *
製品番号			カスタマ需要量 *
電話番号 *
必ず会社名を記載ください。個人への返信は行いません。
備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: